tumour marker

(redirected from cancer marker)

tumour marker

Any specific substance present in increased amounts in serum that may be used for early cancer (CA) detection. Most tumour markers are nonspecific and of little use as screening tools; they may be used to detect recurrence (e.g., CEA in patients with known colorectal and other CAs).  

Examples
Oncofoetal proteins (alpha-fetoprotein) for hepatic carcinoma; CA125 for ovarian CA; CEA for ovarian, lung, breast, pancreas, GI tract CAs; PSA for prostate CA.

tu·mor mark·er

(tū'mŏr mahr'kĕr)
A substance released into the circulation by tumor tissue; its detection in the serum indicates the presence and specific type of tumor.
Synonym(s): tumour marker.

tu·mor mark·er

(tū'mŏr mahr'kĕr)
A substance released into the circulation by tumor tissue; its detection in the serum indicates the presence and specific type of tumor.
Synonym(s): tumour marker, tumour marker.
References in periodicals archive ?
The release noted that the cancer marker RECAF(TM) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests.
In the future, the company intends to expand the test menu to offer among others, fertility, anemia, infectious disease diagnostic, and cancer marker monitoring tests.
Gold's life work and the importance of this new cancer marker.
Under the agreement, in vitro diagnostics leader DakoCytomation receives a worldwide license for commercial use of a Northwest Biotherapeutics antibody that recognizes the key prostate cancer marker, Prostate Specific Membrane Antigen, or PSMA.
After the first four months of chemotherapy, my cancer marker was in the normal range.
We will design, engineer and optimize highly specific biomolecular nanodevices that undergo binding-induced conformational changes upon target binding and, in doing so, signal the presence of the cancer marker.
Even if it does not, it could provide doctors with a useful new cancer marker.
This highlights the importance of an inexpensive, reliable cancer marker test and monitoring tool which BioCurex believes could be fulfilled by its RECAF blood test.
Successful completion of this financing will provide us with capital to continue our development efforts, pursue regulatory approvals and commercialization of the point-of-care rapid test format of our RECAF(TM) cancer marker testing technology, and to commence marketing our other test formats in sectors where regulatory approvals are not required.
In a more recent study evaluating an ovarian cancer marker panel that included leptin, prolactin, osteopontin, IGF-II, macrophage migration inhibitory factor, and CA 125, only CA 125, osteopontin, and IGF-II levels differed significantly between ovarian cancer patients and controls with benign ovarian disease (Anticancer Res.